Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
For refractory complex partial seizures. Sold as Sabril, Vigafyde. Every FDA application for this active ingredient: 3 branded and 27 generic.
As of Nov 13, 2026, FDA lists 30 applications for Vigabatrin (sold as Sabril, Vigafyde), first approved Aug 21, 2009, with 6 new uses approved and 0 published complete response letters.
First approved: Aug 21, 2009
Applications: 30
New uses approved: 6
Complete response letters: 0
Medicare spending, 2025: $26.1M
First approved in the EU: Sep 20, 2018
First approved in Japan: Mar 28, 2016
Safety program: REMS
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Accord Hlthcare
Zydus Lifesciences
Hikma